Table 2.
New standard of care treatment with telaprevir for chronic hepatitis C patients
| References | G | Number of patients | Naïve or re-treatment | Formula of therapy, and duration of treatment (weeks) | SVR rates (%) | Notes |
|---|---|---|---|---|---|---|
| [35] |
G1 |
79 |
naive |
T12PR24 |
61 |
PROVE1 Study |
| 79 |
naive |
T12PR48 |
67 |
|||
| 17 |
naive |
T12PR12 |
35 |
|||
| 75 |
naive |
PR48 |
41 |
|||
| [36] |
G1 |
81 |
naive |
T12PR24 |
69 |
PROVE2 Study |
| 82 |
naive |
T12PR12 |
60 |
|||
| 78 |
naive |
T12P12 |
36 |
|||
| 42 |
naive |
PR48 |
46 |
|||
| [37] |
G1 |
115 |
re-treatment |
T12PR24 |
51 |
PROVE3 Study |
| 113 |
re-treatment |
T12PR48 |
53 |
|||
| 111 |
re-treatment |
T24P24 |
24 |
|||
| 114 |
re-treatment |
PR48 |
14 |
|||
| [38] |
G1 |
363 |
naive |
T12PR |
73 |
ADVANCE Study |
| |
|
364 |
naive |
T8PR |
67 |
|
| |
|
49 |
naïve |
PR48 |
44 |
|
| [39] |
G1 |
145 |
re-treatment |
T12PR48 |
93 |
REALIZE Study |
| |
|
141 |
re-treatment |
Lead-in T12 PR48 |
89 |
|
| |
|
68 |
re-treatment |
PR48 |
24 |
|
| [40] |
G1 |
162 |
naïve |
T12PR24 (RGT) |
92 |
ILLUMINATE Study |
| |
|
160 |
naïve |
T12PR48 (RGT) |
88 |
|
| |
|
118 |
naïve |
T12PR48 (non-RGT) |
64 |
|
| 100 | naïve | Discontinued treatment before wk 20 | 23 |